Ionizable Lipid Nanoparticles With Oxidative Stability for mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing ionizable cationic lipids (ICL) used in lipid nanoparticles (LNPs) for nucleic acid delivery are sensitive to oxidative degradation during storage, compromising their stability and transfection potency.
Innovation Solution
A lipid nanoparticle composition comprising specific ratios and types of ionizable cationic lipids, sterols, phospholipids, and conjugated lipids, including cationic lipids like DLin-KC3-DMA, KC3-01, KC3-OA, KC3-PA, KC3-C17 (8:1), KC3-C15 (C8:1), and Compound 8, with optimized N/P ratios and lipid content percentages, enhances stability and transfection efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ionizable cationic lipids are used in LNP formulations, then transfection activity is achieved, but oxidative stability during storage deteriorates
Solution Approach 1:
The patent modifies the chemical structure of ionizable cationic lipids by changing parameters such as the number of double bonds (unsaturation), chain length, and functional group composition. Specifically, it uses lipids with reduced unsaturation (e.g., monounsaturated instead of polyunsaturated) and optimized chain lengths to decrease susceptibility to oxidation while preserving transfection capability. This directly addresses the contradiction by altering molecular parameters to achieve both stability and activity.
Solution Approach 2:
The patent employs composite LNP formulations containing multiple lipid types in specific ratios, including ionizable cationic lipids, neutral lipids (e.g., cholesterol), and helper lipids. By combining lipids with complementary properties—where some components provide transfection activity and others provide structural stability and oxidative resistance—the formulation achieves both high transfection efficiency and improved storage stability through synergistic interactions.
2Productivity
If LNP formulations are optimized for transfection potency, then delivery efficiency improves, but storage stability compromises
Solution Approach 1:
The patent optimizes critical parameters including lipid composition ratios (e.g., ionizable lipid content, cholesterol content), particle size distribution, and surface charge characteristics. By carefully controlling these parameters—such as maintaining specific mol% ranges of different lipid components and optimizing particle size for cellular uptake—the formulation achieves high transfection efficiency while simultaneously improving storage stability through reduced molecular susceptibility to degradation.
Solution Approach 2:
The patent applies different functional properties to different components within the LNP system. Specific lipid molecules are selected for localized functions: ionizable cationic lipids provide transfection activity at the cellular interface, while neutral lipids and antioxidants provide structural integrity and oxidative protection in the core formulation. This differentiation of local qualities allows simultaneous optimization of both transfection potency and storage stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides improved oxidative stability and transfection efficiency, effectively delivering nucleic acids, particularly mRNA, to cells, including dendritic cells, for vaccine applications.
Implementation Method 1
LNP compositions typically include an ionizable cationic lipid (ICL)... an ionizable cationic lipid at a N/P ratio of 3 to 8 relative to the nucleic acid
Implementation Method 2
Lipid nanoparticles (LNP) are used for the delivery of therapeutic nucleic acids to cells... effectively delivering nucleic acids, particularly mRNA, to cells, including dendritic cells
Data Source
AI summary
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.